ArticleInternational journal of nanomedicine2025
Silk Biowaste Protein Mediated Silver Nanoparticles Synthesis and Analysis of Anti-Inflammatory, Wound Healing, Antidiabetic, Antioxidant, Tyrosinase Inhibition, and Antibacterial Mechanism of Action.
Article in International journal of nanomedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Green-synthesizedRSC advances · 2026Article
- Silver Nanoparticle-Silk Protein Nanocomposites: A Synergistic Biomimetic Approach for Advanced Antimicrobial Applications.Biomimetics (Basel, Switzerland) · 2025Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Silk, a natural biowaste protein from silkworm cocoons called sericin, has promising properties as a biomaterial for several biomedical applications, owing to its excellent biocompatibility, biodegradability, hydrophilicity, and reactivity. Purpose: The synthesis of AgNPs using these biowaste protein materials is more efficient, environmentally friendly, and cost-effective. Methods: In this study, a novel approach was developed to synthesize silver nanoparticles (Scn-AgNPs) using sericin as a reducing agent and to study their anti-inflammatory, wound healing, antidiabetic, antioxidant, tyrosinase inhibitory, and antibacterial mechanisms of action. Results: The initial production of Scn-AgNPs was established by a visual color change to brown, followed by UV-visible spectroscopy, which showed a solid absorption band at 422 nm due to surface plasmon resonance. The mean particle size 82.77 nm with a polydispersity index of 0.387, and -30.8 mV zeta potential specifies the strong stability of the nanoparticles. Scn-AgNPs demonstrated promising wound healing potential, with around 67.72% of wound closure rate at 25 µg/mL concentration. Besides, It also displayed significant anti-inflammatory, antioxidant (in terms of DPPH (75.48%), ABTS (95.04%), SOD (73.92%) potential), antidiabetic properties (95.32% of α-amylase inhibition and 94.42% of α-glucosidase inhibition), and tyrosinase inhibition (27.07%) potentials. Furthermore, the Scn-AgNPs also exhibited significant antibacterial potential with the inhibition zones diameter ranging from 13.84 to 16.90 mm against all the three tested bacteria. Conclusion: The results indicated that Scn-AgNPs could be a potential candidate for various applications, including cosmetics for preparing antioxidant rich gels and nano formulations, in the biomedical field as a component of wound dressing, antibacterial dressing, drug carriers and drug delivery systems, and in environmental sectors as antibacterial agents, food packaging, food additives and in vitro/in vivo monitoring. This study highlights the use of sericin bio-waste materials into valuable resources, endorsing sustainability and enhancing the commercial value of silk-based bio-waste materials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.